ライフサイエンスコーパス: albuminuria

1 FSGS and proteinuria (>46-fold increases in albuminuria).

2 diovascular, and safety outcomes by baseline albuminuria.

3 the glomerular filtration barrier and reduce albuminuria.

4 oint on the basis of the treatment effect on albuminuria.

5 accumulation (ELA), glomerulosclerosis, and albuminuria.

6 by mesangiolysis, capillary ballooning, and albuminuria.

7 imated glomerular filtration rate (eGFR) and albuminuria.

8 by ambulatory blood pressure monitoring) and albuminuria.

9 greatest among those with severely increased albuminuria.

10 all-cause mortality, independent of eGFR and albuminuria.

11 athways for translational research to reduce albuminuria.

12 ross trials and different levels of eGFR and albuminuria.

13 pulse rate, beta-blocker use, and sustained albuminuria.

14 duria, low molecular weight proteinuria, and albuminuria.

15 months of age or a difference in LPS-induced albuminuria.

16 by glycosuria, aminoaciduria, calciuria, and albuminuria.

17 patients with type 2 diabetes and prevalent albuminuria.

18 n, decreasing glomerular hyperfiltration and albuminuria.

19 nostic accuracy of point-of-care testing for albuminuria.

20 e and correlate with renal calcification and albuminuria.

21 pression of a highly sulfated HS domain, and albuminuria.

22 her illuminated the clinical implications of albuminuria.

23 iabetes, body mass index, baseline eGFR, and albuminuria.

24 tion and glomerular leak interact to promote albuminuria.

25 with glomerular leak can combine to increase albuminuria.

26 ns, as expected if podocyte depletion causes albuminuria.

27 induced podocyte foot process effacement and albuminuria.

28 diabetes, cardiovascular disease, eGFR, and albuminuria.

29 c kidney disease in the setting of increased albuminuria.

30 f allele-specific rat models during onset of albuminuria.

31 showed persistent glomerular hyalinosis and albuminuria 96 hours after injection, whereas wild-type

32 Prior studies suggest that albuminuria, a biomarker of endothelial injury, is incre

33 ma cell dyscrasia (dFLC) and nephrotic-range albuminuria (ACR).

34 Albuminuria acts as a marker of progressive chronic kidn

35 ated with CVD and mortality, and, along with albuminuria, adds predictive discrimination to current C

36 Albuminuria affects millions of people, and is an indepe

37 In the absence of albuminuria, age-related reduction in GFR with the corre

38 r filtration rate [eGFR] <60 mL/min/1.73m2), albuminuria (albumin/creatinine ratio >/=3 mg/mmol), and

39 y-induced glomerular injury, as assessed via albuminuria, although the degree of microscopic hematuri

40 showed that administration of AS-IV reduced albuminuria, ameliorated changes in the glomerular and t

41 ur study aimed to describe the prevalence of albuminuria amongst people who inject drugs in London an

42 Our findings suggest the prevalence of albuminuria amongst PWID is twice that of the general po

43 sks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling

44 y disease, with a strong association between albuminuria and amputation.

45 ut not of the G0 allele, develop functional (albuminuria and azotemia), structural (foot-process effa

46 rted renal benefits, including inhibition of albuminuria and cellular crescent formation, similar to

47 cell injury explains the association between albuminuria and COPD, (2) CS-induced albuminuria is link

48 s suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker and fu

49 etic eNOS(-/-) mice significantly attenuated albuminuria and diabetic kidney injury, which were assoc

50 eserved in MC1R-null mice, marked by reduced albuminuria and diminished histologic signs of podocyte

51 ric type 2 diabetics UPPod:CR predicted both albuminuria and eGFR loss.

52 APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, wher

53 P domain protein suppressed diabetes-induced albuminuria and enhanced M2 marker expression.

54 s and assessed for renal injury by measuring albuminuria and examining kidney histology.

55 hannel blocker SKF96365 markedly ameliorated albuminuria and glomerular damage in response to DOCA.

56 betes (T2D), which correlates with increased albuminuria and glomerular damage.

57 IDOL-induced dyslipidemia worsened albuminuria and glomerular macrophage accumulation but h

58 kout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.

59 Darunavir and darunavir + zidovudine reduced albuminuria and histologic kidney injury and normalized

60 deletion of Drp1 in diabetic mice decreased albuminuria and improved mesangial matrix expansion and

61 Deletion of DUSP4 exacerbated albuminuria and increased mesangial expansion and glomer

62 with sham-operated controls, Px-UNx induced albuminuria and increased urine markers of kidney injury

63 i-miR-92a after disease initiation prevented albuminuria and kidney failure, indicating miR-92a inhib

64 redispose animals to hypertension-associated albuminuria and kidney injury.

65 with data on serum creatinine and change in albuminuria and more than 50 events on outcomes of inter

66 betes, phenyl sulfate administration induces albuminuria and podocyte damage.

67 h demonstrated that Shroom3 knockdown led to albuminuria and podocyte foot process effacement.

68 cy in vivo surprisingly reduced the level of albuminuria and podocyte injury in models of both diabet

69 ion of mTOR is most commonly associated with albuminuria and podocyte injury, but has also been linke

70 ups, after adjustment and stratification for albuminuria and potassium, and when modeling RAS inhibit

71 have consistently demonstrated reduction of albuminuria and preservation of kidney function.

72 dney disease, and adverse events, as well as albuminuria and progression of retinopathy in trials don

73 ted podocyte detachment, podocyte depletion, albuminuria and progression.

74 feriprone significantly delayed the onset of albuminuria and reduced blood urea nitrogen concentratio

75 e determined whether canagliflozin decreases albuminuria and reduces renal function decline independe

76 late neonatal death associated with massive albuminuria and renal failure.

77 f EVR with early CNI withdrawal after HTx on albuminuria and renal function seem dissociated; hence,

78 es available, no significant associations of albuminuria and retinal vessel diameters with depression

79 istency of the association between change in albuminuria and risk of end-stage kidney disease in a la

80 C-terminal CUBN variants are associated with albuminuria and slightly increased GFR in meta-analyses

81 mated treatment effects on 6-month change in albuminuria and the composite clinical endpoint of treat

82 se renal hyperfiltration, thereby increasing albuminuria and the progression of renal disease.

83 etween treatment effects on early changes in albuminuria and treatment effects on clinical endpoints

84 Albuminuria and tubular atrophy are among the highest ri

85 without diabetes, cardiovascular disease, or albuminuria and with an eGFR of 25 ml/min per 1.73 m(2)

86 ative renal hypoxia that was associated with albuminuria and with increased RPF, fat mass, and insuli

87 , 2.6; 95% CI, 1.8 to 3.8, respectively) and albuminuria and/or eGFR<60 ml/min per 1.73 m(2) (OR, 2.9

88 haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determina

89 r filtration rate <60 mL.min(-1).1.73 m(-2), albuminuria, and diuretic use (each P interaction <0.05)

90 However, serum creatinine concentration, albuminuria, and glomerular expression of ETS-1 and two

91 but significantly attenuated hyperglycemia, albuminuria, and glomerulosclerosis and increased podocy

92 nd podocytes leads to defects and depletion, albuminuria, and glomerulosclerosis.

93 s-induced endothelial injury, podocyte loss, albuminuria, and glomerulosclerosis.

94 nant-negative Orai1 mutant (E108Q) increases albuminuria, and in vivo injection of BTP2 exacerbates a

95 atment also improved renal function, reduced albuminuria, and inhibited expression of profibrotic mar

96 dentified prior to onset of hyperglycemia or albuminuria, and monitored non-invasively by urinary pel

97 nd prevented the development of proteinuria, albuminuria, and nephrinuria.

98 ogression and mortality, adjusting for eGFR, albuminuria, and other confounding characteristics.

99 ris DBA resulted in improved renal function, albuminuria, and pathology, including measurements of gl

100 on, glomerular basement membrane thickening, albuminuria, and podocyte dropout.

101 o losartan, Ly normalized blood pressure and albuminuria, and prevented CKD progression more effectiv

102 ependently associated with renal impairment, albuminuria, and proximal renal tubular dysfunction.

103 resulted in reduced serum creatinine level, albuminuria, and renal histologic changes (mesangial exp

104 e leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thu

105 evel, reduced glomerular hyperfiltration and albuminuria, and suppression of advanced glycation end-p

106 e physical stress on the filtration barrier, albuminuria, and the oxygen demand for tubular reabsorpt

107 modification by subgroups of baseline eGFR, albuminuria, and use of renin-angiotensin system (RAS) b

108 7 to -0.24 mL/min/1.73m2/year) and worsening albuminuria (aOR = 2.3; 95% CI = 1.3-4.0).

109 .1; 95% confidence interval [CI] = 1.0-4.4), albuminuria (aOR = 5.8; 95% CI = 3.7-9.0), and proximal

110 The clinical importance of albuminuria as a predictor of kidney disease progression

111 rts, lending support to the use of change in albuminuria as a surrogate endpoint for end-stage kidney

112 Change in albuminuria as a surrogate endpoint for progression of c

113 Our results support a role for change in albuminuria as a surrogate endpoint for the progression

114 d surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised

115 2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes

116 Multivariable analyses confirmed eGFR and albuminuria as key risk factors for predicting adverse a

117 mean serum creatinine concentration and less albuminuria, as well as less histologic evidence of glom

118 ng everolimus (EVR), but the significance of albuminuria associated with EVR treatment after early CN

119 (eGFR 84 +/- 11.7 ml/min/1.73m(2)) and norm-albuminuria at baseline, UPPod:CR was associated with eG

120 account for imprecision in the estimation of albuminuria at the participant level.

121 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion

122 cluding podocytopathy, diabetic nephropathy, albuminuria, autosomal dominant polycystic kidney diseas

123 ent across patients with different levels of albuminuria, but absolute benefits are greatest among th

124 Albuminuria, but not estimated glomerular filtration rat

125 resulted in nephritic urine by dipstick and albuminuria by enzyme-linked immunosorbent assay, and mo

126 unction of the renal microcirculation causes albuminuria by increasing glomerular capillary wall perm

127 3-1.70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was

128 sk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and re

129 minuria (increase >/=10%/year with change in albuminuria category).

130 people with GFR 45-59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1).

131 rences in the other variables used to define albuminuria class transition altered the average drug ef

132 In the norm-albuminuria cohort (n = 75) baseline UPPod:CR was associ

133 ely to experience eGFR decline and worsening albuminuria compared with HIV-uninfected individuals.

134 eGFR and albuminuria contributed multiplicatively (eg, adjusted H

135 er, only Podo-GC-A KO mice developed massive albuminuria (controls: 35-fold; KO: 5400-fold versus bas

136 Albuminuria could identify patients with COPD in whom an

137 Taken together, albuminuria decreases Klotho expression through increase

138 Albuminuria due to reduced cubilin function could be an

139 ardiovascular outcomes were glycohemoglobin, albuminuria, duration of diabetes mellitus, systolic blo

140 Glycohemoglobin, albuminuria, duration of diabetes mellitus, systolic blo

141 ars or older, they had a repeated measure of albuminuria during an elapsed period of 8 months to 4 ye

142 m restriction substantially reduced residual albuminuria during fixed dose angiotensin-converting enz

143 Reduction of residual albuminuria during single-agent renin-angiotensin-aldost

144 l/min/1.73m(2)/year showed that UPPod:CR and albuminuria each improved the AUC similarly such that co

145 and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitor

146 or to development of either hyperglycemia or albuminuria, fa/fa rats were hyperinsulinemic with high

147 particularly in patients with high baseline albuminuria; for patients with low baseline levels of al

148 In the intention-to-treat analysis, albuminuria (geometric mean) was 1060 (95% confidence in

149 a in these patients had a high proportion of albuminuria, glomerular diseases such as steroid-resista

150 ity lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate, smoking, and ex

151 ervention with a NOX1/NOX4 inhibitor reduced albuminuria, glomerular hypertrophy, and mesangial matri

152 evelop diabetic nephropathy, exhibiting less albuminuria, glomerular hypertrophy, podocyte injury, an

153 sex, higher baseline serum creatinine value, albuminuria, greater severity of acute kidney injury, an

154 CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, and CKD stages 3-5 was defined as

155 patients with nondiabetic CKD stages 1-3 and albuminuria >300 mg/24 h despite ramipril at 10 mg/d and

156 a man with diabetes, cardiovascular disease, albuminuria >300 mg/d, and an eGFR of 20 ml/min per 1.73

157 filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria >=30 mg per 24 hours) for more than 3 months

158 ssion (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria >=300 mg per 24 hours, or rapid decline in e

159 Podocyte markers and albuminuria had overlapping AUC contributions, as expect

160 Change in albuminuria has strong biological plausibility as a surr

161 However, the true significance of albuminuria has yet to be fully defined.

162 with chronic kidney disease with or without albuminuria have not been well studied.

163 gliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95% CI, 0.67 to 0.79) a

164 d traits such as glomerular filtration rate, albuminuria, hypertension, electrolyte and metabolite le

165 flozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renopro

166 in moderate and severe stages of CKD-related albuminuria improved the most at 12-month follow-up (by

167 ting the NPY2R in vivo significantly reduced albuminuria in adriamycin-treated glomerulosclerotic mic

168 ly suppressed diabetic glomerular injury and albuminuria in both WT and miR-146a(-/-) animals.

169 ) and dietary sodium restriction on residual albuminuria in CKD.

170 ed into phenyl sulfate in the liver, reduces albuminuria in diabetic mice.

171 ular endothelial cell (GEnC) dysfunction and albuminuria in diabetic nephropathy.

172 ic kidneys appears to be a primary driver of albuminuria in fa/fa rats and thereby an under-recognize

173 Albuminuria in maintenance heart transplantation (HTx) i

174 in ER-stressed podocytes, as well as inhibit albuminuria in our NS model.

175 th basal and predicted 2-year progression of albuminuria in patients with microalbuminuria.

176 rm and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and establi

177 er-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevale

178 (GLP)-1 analogs such as liraglutide improved albuminuria in patients with type 2 diabetes in large ra

179 as well as blood pressure, body weight, and albuminuria in people with diabetes.

180 841K/E1841K) mice exhibited mildly increased albuminuria in response to high salt; severe albuminuria

181 neralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with

182 a, and in vivo injection of BTP2 exacerbates albuminuria in streptozotocin-induced and Akita diabetic

183 ce of reduced glomerular filtration rate and albuminuria in the Fontan population; however, the long-

184 ociated; hence, the clinical significance of albuminuria in this setting is uncertain and should not

185 Furthermore, the prevention of albuminuria in treated mice was associated with preserva

186 The main outcome measure was any albuminuria including both microalbuminuria and macroalb

187 by clinically relevant eGFR subgroups or by albuminuria, including patients with eGFR as low as 20 m

188 iated with greater eGFR decline or worsening albuminuria (increase >/=10%/year with change in albumin

189 Each SD log-transformed albuminuria increased hazards of incident COPD-related h

190 ive pulmonary disease (COPD) frequently have albuminuria (indicative of renal endothelial cell injury

191 Albuminuria is a hallmark of kidney disease of various e

192 Albuminuria is a key biomarker for cardiovascular diseas

193 Albuminuria is an independent risk factor for the progre

194 discovering signaling pathways that modulate albuminuria is desirable.

195 Albuminuria is high amongst people who inject drugs comp

196 ssociation between capillary rarefaction and albuminuria is lacking.

197 between albuminuria and COPD, (2) CS-induced albuminuria is linked to increases in the oxidative stre

198 The key cell that prevents albuminuria is the terminally differentiated glomerular

199 DKD phenotypes, including glycemic control, albuminuria, kidney function, and kidney function declin

200 c nephropathy" progressing through stages of albuminuria, leading to decline in glomerular filtration

201 onsistent with recent studies reporting that albuminuria leads to impairment of kidney function.

202 afety outcomes were mostly consistent across albuminuria levels including increased risks for amputat

203 , followed by higher mean HbA(1c), sustained albuminuria, longer duration of type 1 diabetes, higher

204 sion reduced the development of hypertrophy, albuminuria, loss of GEnC fenestrations and protected ag

205 ivity, males had progressive glomerulopathy, albuminuria, loss of podocytes, and tubulointerstitial f

206 We assessed the albuminuria-lowering effect of the sodium-glucose co-tra

207 ve glucose control can be renoprotective and albuminuria-lowering treatments can slow the deteriorati

208 Likewise, compared with patients with no albuminuria (<30 mg/g), those microalbuminuria and those

209 Albuminuria may be a biomarker of generalized (i.e., mic

210 vel data and quantified percentage change in albuminuria, measured as change in urine albumin-to-crea

211 ts with preserved lung function, mean age at albuminuria measurement was 60 years, 51% were never-smo

212 UK routine primary care database and limited albuminuria measurements.

213 ion: plasma markers of endothelial function, albuminuria, measurements of skin and muscle microcircul

214 oethidium oxidation, and increased levels of albuminuria, mesangial matrix accumulation, and urinary

215 albuminuria in response to high salt; severe albuminuria, nephrinuria, FSGS, and podocyte foot efface

216 feration did not translate into a decline of albuminuria nor in a sustained reduction in sclerotic le

217 APA-KO mice developed a significant rise in albuminuria not observed in AngII-treated wild-type mice

218 nteraction), with a decreasing prevalence of albuminuria observed only among adults younger than 65 y

219 Progressive albuminuria occurred in Gsalpha-deficient mice.

220 0 copies) were significantly associated with albuminuria (odds ratio [OR], 3.2; 95% confidence interv

221 stricting analyses to patients with baseline albuminuria of more than 30 mg/g (ie, 3.4 mg/mmol; R(2)

222 n criteria were quantifiable measurements of albuminuria or proteinuria at baseline and within 12 mon

223 Late sirolimus treatment did not reduce albuminuria or the progression of glomerulosclerosis.

224 End points were annual change in eGFR and albuminuria over 2 years of follow-up.

225 d to eGFR slope were UPPod:CR (P < 0.01) and albuminuria (P < 0.01).

226 UPPod:CR was associated with development of albuminuria (P = 0.007) and, in the tertile with both no

227 those with moderately and severely increased albuminuria (P heterogeneity<0.001).

228 rved in participants with severely increased albuminuria (P heterogeneity=0.004).

229 ts in participants with moderately increased albuminuria (P heterogeneity=0.03), but no effect modifi

230 tent across studies irrespective of baseline albuminuria (p(trend)=0.66) and use of RAS blockade (p(h

231 ions in participants with severely increased albuminuria (placebo-subtracted difference 3.01 ml/min p

232 BIO alone improved albuminuria, podocyte density in superficial and juxtame

233 Levels of albuminuria, podocyte injury and podocyte number were si

234 exhibited significantly increased levels of albuminuria, podocyte injury, and loss of podocytes comp

235 proliferation, basement membrane thickening, albuminuria, podocyte loss, and aspects of FSGS during a

236 anti-podocyte autoantibodies, the chips show albuminuria proportional to patients' proteinuria, pheno

237 ey disease", "chronic renal insufficiency", "albuminuria", "proteinuria", and "randomized controlled

238 cohort (n = 128), we measured time-of-biopsy albuminuria, proteinuria, and plasmin (ogen) uria for co

239 inute per 1.73 m(2) of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >3

240 emapticap pegol (NOX-E36) shows long-lasting albuminuria-reducing effects in diabetic nephropathy.

241 h study medication, PARI did provide further albuminuria reduction (P=0.04 LS + PARI versus LS + PLAC

242 tio, C-reactive protein, angiotensin II, and albuminuria reduction and with increased glucose disposa

243 mean albuminuria to 0.7 (ie, 30% decrease in albuminuria) relative to the control will provide an ave

244 ver, mean serum creatinine concentration and albuminuria remained lower in ES allograft recipients th

245 Kallistatin overexpression exacerbated albuminuria, renal fibrosis, inflammation, and oxidative

246 ype 1 diabetes (T1D) and relate the ratio to albuminuria, renal plasma flow (RPF), fat mass, and insu

247 type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more.

248 Neither approaches decreased albuminuria significantly, whereas diuretics did signifi

249 eks of age led to a significant reduction in albuminuria, similar to that observed with renin-angiote

250 at target: glycohemoglobin, blood pressure, albuminuria, smoking, and low-density lipoprotein choles

251 and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of t

252 ntermediate renal outcomes of transitions in albuminuria stages (ie, transitions between normoalbumin

253 agliflozin group versus placebo according to albuminuria status at baseline (normoalbuminuria: UACR <

254 albumin excretion, irrespective of patients' albuminuria status at baseline.

255 or subpopulations based on baseline eGFR or albuminuria status were analyzed or an eGFR decline of >

256 lar disease, according to patients' baseline albuminuria status.

257 luding increased risks for amputation across albuminuria subgroups (P heterogeneity=0.66).

258 ed the annual loss of kidney function across albuminuria subgroups, with greater absolute reductions

259 re for the comprehensive analysis of a major albuminuria susceptibility locus detected in these model

260 GEC(HO-1) rats older than 6 months developed albuminuria that was detectable at 6 months and became s

261 estimated glomerular filtration rate, (micro)albuminuria, the use of lipid-modifying and blood pressu

262 For each SD increase in log-transformed albuminuria, there was 2.81% greater FEV(1) decline (95%

263 ia; for patients with low baseline levels of albuminuria this association is less certain.

264 treatments that decrease the geometric mean albuminuria to 0.7 (ie, 30% decrease in albuminuria) rel

265 001 versus RS + PLAC), and LS + PARI reduced albuminuria to 683 (95% confidence interval, 502 to 929)

266 LS + PLAC reduced albuminuria to 717 (95% confidence interval, 512 to 1005

267 analysis to relate the treatment effects on albuminuria to those on the clinical endpoint across stu

268 mg/g) and 760 (7.5%) with severely increased albuminuria (UACR >300 mg/g) at baseline.

269 of podocytes, key cells in the prevention of albuminuria, under diabetic conditions.

270 ccelerated development of glomerulopathy and albuminuria upon streptozotocin (STZ)-induced hyperglyce

271 In type 2 diabetics with micro- or macro-albuminuria UPPod:CR and albuminuria were equally good a

272 rticipants (22.3%) with moderately increased albuminuria (urinary albumin/creatinine ratio [UACR] 30-

273 GFR) <60 mL.min(-1).1.73 m(-2) and 19.0% had albuminuria (urinary albumin:creatinine ratio >=30 mg/g)

274 MTP-131 significantly inhibited increases in albuminuria, urinary H(2)O(2), and mesangial matrix accu

275 Albuminuria (urine albumin-to-creatinine ratio >/=30 mg/

276 known history of type 2 diabetes, increased albuminuria (urine albumin-to-creatinine ratio [UACR] 30

277 Albuminuria (urine albumin-to-creatinine ratio) was meas

278 was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean FEV(1) decline was 31

279 ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks an

280 Albuminuria was associated with greater lung function de

281 In RARE-LacZ mice, Adriamycin-induced heavy albuminuria was associated with reduced RA/RAR activity

282 Change in albuminuria was consistently associated with subsequent

283 d by iohexol and p-aminohippurate clearance; albuminuria was estimated by urine albumin-to-creatinine

284 ramatic reduction was found in diuresis, and albuminuria was evident after administration of 1% NaCl

285 but no effect modification was observed when albuminuria was fitted as a continuous variable (P heter

286 cant heterogeneity in the temporal trend for albuminuria was noted by age (P = .049 for interaction)

287 the estimated glomerular filtration rate and albuminuria were also analyzed.

288 ith micro- or macro-albuminuria UPPod:CR and albuminuria were equally good at predicting eGFR loss.

289 der light microscope, severe proteinuria and albuminuria were found in these podocyte-specific knocko

290 Risk factors associated with albuminuria were HIV (aOR 4.11 [95% CI 1.37-12.38]); fol

291 ms for CKD account for both reduced eGFR and albuminuria; whether each measure associates with greate

292 Additionally, nephrotic-range albuminuria with an albumin-to-creatinine-ratio (ACR) >2

293 Canagliflozin lowered albuminuria with greater proportional reductions in thos

294 Previously we demonstrated massive albuminuria with hypertension in uninephrectomized, aldo

295 ial-specific Epas1 gene deletion accentuated albuminuria with severe podocyte lesions and recruitment

296 ntified associations of percentage change in albuminuria with subsequent end-stage kidney disease usi

297 imated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery dis

298 e with the mouse-specific NOX-E36 attenuated albuminuria without any change in systemic hemodynamics,

299 lin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention

300 alterations of Klotho expression induced by albuminuria, yet the underlying mechanisms are unclear.